Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Global $22 Billion Adult Vaccine Market to 2024 Featuring Key Players - GlaxoSmithKline, Merck, Sanofi, and Pfizer | ||
By: PR Newswire Association LLC. - 13 Dec 2018 | Back to overview list |
|
DUBLIN, Dec. 13, 2018 /PRNewswire/ -- The "Adult Vaccine Market, Global Analysis By Disease (Influenza, Cervical Cancer, Zoster, MMR , Pneumonia, Meningitis, Hepatitis, Tap , Varicella & Travel & Miscellaneous Vaccine) & Companies" report has been added to ResearchAndMarkets.com's offering. Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024 Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable diseases. Several organizations such as Global Immunization Vision and Strategy (GIVS), WHO's Global Vaccine Action Plan, The GAVI Alliance are putting their best to reduce the occurrence of vaccine-preventable diseases around the world which certainly is driving the adult vaccine market sturdily. Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period. Almost 350 Million Adults get vaccinated by 2024 Due to the increasing prevalence of diseases and growing awareness regarding the vaccine-preventable diseases, it is estimated that by the year 2024, nearly 350 million adults get vaccinated; in order to protect themselves from diseases. Some of the vaccines which hold a considerable share in terms of adult vaccination include Influenza, Hepatitis, HPV and Pneumonia vaccine. Company Analysis: GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently with vaccine business globally. These companies have been studied thoroughly in the report. Key Topics Covered: 1. Research Findings For more information about this report visit https://www.researchandmarkets.com/research/j946j7/global_22?w=5 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Laura Wood, Senior Manager View original content:http://www.prnewswire.com/news-releases/global-22-billion-adult-vaccine-market-to-2024-featuring-key-players---glaxosmithkline-merck-sanofi-and-pfizer-300765031.html SOURCE Research and Markets |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |